SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1876)3/2/1999 7:55:00 PM
From: Bob Swift  Read Replies (1) of 10280
 
Peter,
Correct me if I am wrong but I don't remember a case where more than a few % difference was recorded. It was never very clear to me why we don't see a drastic reduction of side effect by 50% or 100%. I tend to attribute the reduced side effect and quicker onset of action etc to the smaller doses used and experimental variations as patient response can be rather subjective. The oxybutynin result is an example that I don't know what to believe. That said, even a few % can be significant in the hands of the big pharms if they want to push it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News